FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2092491069> ?p ?o ?g. }

• W2092491069 endingPage "951" @default.
• W2092491069 startingPage "951" @default.
• W2092491069 abstract "Real world outcomes of adding rapid-acting insulin versus switching to analog premix insulin among US patients with type 2 diabetes treated with insulin glargine Raymond Miao,1 Wenhui Wei,1 Onur Baser,2,3 Lin Xie2 1Sanofi US, Bridgewater, NJ, USA; 2STATinMED Research, Ann Arbor, MI, USA; 3Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA Introduction: Patients with type 2 diabetes mellitus (T2DM) often require intensification of basal insulin therapy. This retrospective, observational study compared real-world outcomes in US patients with T2DM treated with insulin glargine who added a rapid-acting insulin (RAI) (basal–bolus approach) with those who switched to premixed insulin (PMX). Methods: The national US IMPACT® database was used to identify data from adult patients (≥18 years of age) with T2DM who added bolus RAI to insulin glargine (GLA + RAI) or who switched from GLA to PMX between 2001 and 2009. A stringent 1:1 propensity score-matching method was used to address the selection bias by matching GLA + RAI patients and PMX patients. Clinical and economic outcomes were determined for 1 year after the initial pharmacy claim for RAI or for PMX. Outcomes included treatment persistence and adherence, average insulin doses, glycated hemoglobin (A1C) levels, the prevalence and incidence of hypoglycemia, and health care costs/utilization. Analysis was carried out using an intent-to-treat approach. Results: The study included data from 746 propensity-matched patients (n = 373 in each cohort). Treatment persistence and adherence were higher in the GLA + RAI cohort. There was no significant difference in A1C reduction from baseline and the number of patients achieving target A1C levels of <7% in each cohort. The incidence of hypoglycemic events was also similar in both groups. However, during follow-up, many patients (48.8%) who initially switched from insulin glargine to PMX crossed back over to use GLA and/or RAI as part of their regimen. Health care costs and utilization levels were not significantly different. Conclusion: Clinical and economic outcomes were similar in T2DM patients who added RAI to GLA and in those who switched to PMX, but a basal–bolus strategy appears to be associated with better treatment persistence and adherence. Keywords: type 2 diabetes mellitus, insulin glargine, rapid-acting insulin, premixed insulin, clinical outcomes, treatment persistence" @default.
• W2092491069 created "2016-06-24" @default.
• W2092491069 creator A5011438418 @default.
• W2092491069 creator A5022873764 @default.
• W2092491069 creator A5048953246 @default.
• W2092491069 creator A5064447813 @default.
• W2092491069 date "2013-09-01" @default.
• W2092491069 modified "2023-09-25" @default.
• W2092491069 title "Real world outcomes of adding rapid-acting insulin versus switching to analog premix insulin among US patients with type 2 diabetes treated with insulin glargine" @default.
• W2092491069 cites W1886102551 @default.
• W2092491069 cites W1908020091 @default.
• W2092491069 cites W1976304072 @default.
• W2092491069 cites W1977389382 @default.
• W2092491069 cites W1984121983 @default.
• W2092491069 cites W1984209835 @default.
• W2092491069 cites W1987535239 @default.
• W2092491069 cites W1990924858 @default.
• W2092491069 cites W1996441843 @default.
• W2092491069 cites W2000611601 @default.
• W2092491069 cites W2034055449 @default.
• W2092491069 cites W2040045465 @default.
• W2092491069 cites W2041064480 @default.
• W2092491069 cites W2041599069 @default.
• W2092491069 cites W2046869249 @default.
• W2092491069 cites W2057595002 @default.
• W2092491069 cites W2059338882 @default.
• W2092491069 cites W2060255598 @default.
• W2092491069 cites W2063337698 @default.
• W2092491069 cites W2076583826 @default.
• W2092491069 cites W2083111645 @default.
• W2092491069 cites W2090332473 @default.
• W2092491069 cites W2096539888 @default.
• W2092491069 cites W2111876001 @default.
• W2092491069 cites W2114369760 @default.
• W2092491069 cites W2139062201 @default.
• W2092491069 cites W2148392045 @default.
• W2092491069 cites W2150291618 @default.
• W2092491069 cites W2154392339 @default.
• W2092491069 cites W2168442288 @default.
• W2092491069 cites W2319983832 @default.
• W2092491069 cites W2411539137 @default.
• W2092491069 cites W2554729258 @default.
• W2092491069 doi "https://doi.org/10.2147/ppa.s49287" @default.
• W2092491069 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3786817" @default.
• W2092491069 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24086105" @default.
• W2092491069 hasPublicationYear "2013" @default.
• W2092491069 type Work @default.
• W2092491069 sameAs 2092491069 @default.
• W2092491069 citedByCount "14" @default.
• W2092491069 countsByYear W20924910692015 @default.
• W2092491069 countsByYear W20924910692016 @default.
• W2092491069 countsByYear W20924910692017 @default.
• W2092491069 countsByYear W20924910692019 @default.
• W2092491069 countsByYear W20924910692020 @default.
• W2092491069 countsByYear W20924910692022 @default.
• W2092491069 countsByYear W20924910692023 @default.
• W2092491069 crossrefType "journal-article" @default.
• W2092491069 hasAuthorship W2092491069A5011438418 @default.
• W2092491069 hasAuthorship W2092491069A5022873764 @default.
• W2092491069 hasAuthorship W2092491069A5048953246 @default.
• W2092491069 hasAuthorship W2092491069A5064447813 @default.
• W2092491069 hasBestOaLocation W20924910691 @default.
• W2092491069 hasConcept C104863432 @default.
• W2092491069 hasConcept C126322002 @default.
• W2092491069 hasConcept C134018914 @default.
• W2092491069 hasConcept C17923572 @default.
• W2092491069 hasConcept C2775927303 @default.
• W2092491069 hasConcept C2776664568 @default.
• W2092491069 hasConcept C2777180221 @default.
• W2092491069 hasConcept C2777538456 @default.
• W2092491069 hasConcept C2779306644 @default.
• W2092491069 hasConcept C2779920387 @default.
• W2092491069 hasConcept C2780668416 @default.
• W2092491069 hasConcept C2780677441 @default.
• W2092491069 hasConcept C2910068830 @default.
• W2092491069 hasConcept C3019948211 @default.
• W2092491069 hasConcept C512399662 @default.
• W2092491069 hasConcept C555293320 @default.
• W2092491069 hasConcept C71924100 @default.
• W2092491069 hasConceptScore W2092491069C104863432 @default.
• W2092491069 hasConceptScore W2092491069C126322002 @default.
• W2092491069 hasConceptScore W2092491069C134018914 @default.
• W2092491069 hasConceptScore W2092491069C17923572 @default.
• W2092491069 hasConceptScore W2092491069C2775927303 @default.
• W2092491069 hasConceptScore W2092491069C2776664568 @default.
• W2092491069 hasConceptScore W2092491069C2777180221 @default.
• W2092491069 hasConceptScore W2092491069C2777538456 @default.
• W2092491069 hasConceptScore W2092491069C2779306644 @default.
• W2092491069 hasConceptScore W2092491069C2779920387 @default.
• W2092491069 hasConceptScore W2092491069C2780668416 @default.
• W2092491069 hasConceptScore W2092491069C2780677441 @default.
• W2092491069 hasConceptScore W2092491069C2910068830 @default.
• W2092491069 hasConceptScore W2092491069C3019948211 @default.
• W2092491069 hasConceptScore W2092491069C512399662 @default.
• W2092491069 hasConceptScore W2092491069C555293320 @default.
• W2092491069 hasConceptScore W2092491069C71924100 @default.
• W2092491069 hasLocation W20924910691 @default.
• W2092491069 hasLocation W20924910692 @default.

• next